.

As a member of the Heath Care Department, Sandrine focuses her practice on the defense of health care professionals and institutions in medical malpractice and professional liability litigation.

Sandrine completed her undergraduate degree at the University of Pittsburgh, with degrees in Philosophy and Classics. She then attended the University of Pittsburgh School of Law, where she graduated with her J.D. Throughout her studies, Sandrine assisted in the development of online courses for professors of the University’s graduate schools of Medicine, Nursing, Law, and Public and International Affairs.

During law school, Sandrine worked at the Allegheny County Office of the Public Defender where she represented defendants in preliminary hearings. Prior to joining Marshall Dennehey, Sandrine gained valuable experience at one of Pittsburgh’s leading civil litigation defense firms. 

    • University of Pittsburgh School of Law (J.D., 2023)
    • University of Pittsburgh (B.A., summa cum laude, 2020)
    • Pennsylvania, 2023

Thought Leadership

The Quarterly Dose

An Overview of the Protections Afforded by the Peer Review Protection Act

November 1, 2025

As scientific and medical advancements have accelerated, so has the complexity of medical decision-making, exposing a need for standardization in the United States. In 1952, the Joint Commission created the mandatory clinical peer review process. Often referred to as “medical peer review,” it is the process by which health care providers establish and maintain reliable standards of quality in patient care. Clinical peer review entails periodic meetings of professional health care providers to evaluate the quality and efficiency of the services performed by other professional health care providers within the same hospital or health system. Today, countries with reputations for the most exceptional health care all mandate clinical peer review processes. In the United States, the clinical peer review process is so trusted to maintain and improve the quality of health care that every state has enacted a statute preventing certain information and documents discussed in peer review meetings from disclosure in litigation. In 1974, the Pennsylvania legislature enacted the Peer Review Protection Act (PRPA) to provide an evidentiary privilege to protect the “proceedings and documents of a review committee,” conducting peer review activities by professional health care providers, in conformity with its provisions. Reginelli v. Boggs, 181 A.3d 293, 296 (Pa. 2018). The PRPA’s evidentiary privilege is set forth in Section 425.4: The proceedings and records of a review committee shall be held in confidence and shall not be subject to discovery or introduction into evidence in any civil action against a professional health care provider arising out of the matters which are the subject of evaluation and review by such committee and no person who was in attendance at a meeting of such committee shall be permitted or required to testify in any such civil action as to any evidence or other matters produced or presented during the proceedings of such committee or as to any findings, recommendations, evaluations, opinions or other actions of such committee or any members thereof. Between 2018 and 2021, courts both narrowed and broadened the application of this privilege. Narrowing: Only “Peer Review Committees” Can Assert the Privilege In Reginelli v. Boggs, the Pennsylvania Supreme Court held the defendants were not entitled to this privilege primarily because the physician’s employer was not a “professional health care provider” covered under the PRPA. UPMC Emergency Medicine, Inc. (ERMI) staffed the physician to Monongahela Valley Hospital (MVH) and was therefore the physician’s employer. The court held ERMI was not a “professional health care provider” because it was not regulated and licensed to practice medicine. The PRPA defines the term “professional health care providers” as “individuals or organizations who are approved, licensed or otherwise regulated to practice or operate in the health care field under the laws of the Commonwealth.” Because the PRPA’s language explicitly states the “individual or organization be `approved, licensed or otherwise regulated to practice or operate in the health care field under the laws of the Commonwealth- to benefit from the privilege—and the employer at issue was not—the court found the PRPA privilege did not apply. Furthermore, the court found each of the defendants could only be construed as mere “review organizations” that engaged only in a process of reviewing professional qualifications credentialing). Therefore, they were not “review committees” under the PRPA. The PRPA defines a “review organization” as “any committee engaging in peer review....” Although the language of Section 425.4 suggests it pertains to review organizations, the substantive text sets forth confidentiality mandates and testimonial privileges relating to the work and records of review committees. Since the PRPA privilege does not explicitly extend to any review organization that merely conducts credentialing review, the defendants did not qualify for the privilege. Here, the court determined that MVH’s physician merely reviewed the credentials of hospital staff and did not engage in review of the quality and efficiency of the services staff performed. Narrowing: Credentialing Files are Not Protected In Estate of Krappa v. Lyons, the Pennsylvania Superior Court interpreted the PRPA and Reginelli to mean a credentialing file will not be entitled to the PRPA’s evidentiary privilege if it (1) consists entirely of credentialing materials, and (2) was maintained by the hospital’s “credentialing committee.” In Krappa, a patient’s estate brought suit alleging a delay in diagnosis after the patient had died of cancer. During discovery, the estate sought unredacted copies of the medical center’s files concerning two physicians who treated the patient. As discussed in Reginelli, the Superior Court determined credentialing files generated and maintained by a hospital’s credentialing committee are not protected under the PRPA because a credentialing committee does not qualify as a “review committee” engaging in peer review. Narrowing: Event Reports, Root-Cause Analyses are Not Protected In Ungurian v. Beyzman, the Pennsylvania Superior Court articulated that the PRPA privilege does not encompass event reports and root-cause analyses where there is no indication those documents were generated “exclusively for a PRPA 'review committee.' This was a case where the patient’s mother brought a medical malpractice action against physicians, hospital staff, clinics, corporations, and the hospital itself alleging their collective negligence caused the total and permanent incapacity of her child who had undergone a cystoscopy at the hospital. The mother-plaintiff sought to compel various documents, including event reports and root cause analysis, and the defendants appealed arguing protections pursuant to the federal Patient Safety and Quality Improvement Act of 2005 and PRPA. Consistent with the Superior Court’s reasoning in Lyons, the court reasoned that, because neither event reports nor root-cause analyses were generated in the course of peer review and merely constituted business records of the hospital, these documents were not entitled to the privilege. Broadening: Privilege Extends to Peer Review as a Function, not just a “Peer Review Committee” In Leadbitter v. Keystone Anesthesia Consultants, Ltd., the Pennsylvania Supreme Court expanded the potential applicability of the PRPA’s evidentiary privilege in contrast to its opinion in Reginelli where, consistent with the plain language of § 425.3-425.4, the court found the title or name of the body conducting the review was determinative of whether the privilege would apply. Here, however, the Leadbitter court articulated that it is instead the actual function or “activity” of a review organization/committee which determines whether the privilege applies. In this case, a physician applied to be appointed to the medical staff of St. Clair Hospital and for orthopedic surgery clinical privileges. After performing surgery on a patient, the patient suffered a series of strokes and filed a medical malpractice suit against the hospital, seeking that they produce documents relating to the physician’s credentials, as they claimed the physician lacked expertise. The hospital denied the requests, arguing the PRPA privilege applied because the work of their credentials committee was multifaceted and included peer review. Specifically, the hospital argued that this work included both privileging and credentialing and that, because privileging is covered by the PRPA as a peer review activity, the hospital was entitled to statutory protection. It pointed out—and the Leadbitter court acknowledged—that Reginelli’s reasoning was limited to credentialing review for purposes of appointment to a hospital’s medical staff. The Leadbitter court agreed that privileging is distinct from credentialing as it involves giving the physician permission to treat patients at the hospital, and not merely to exercise political rights in relation to staff and committee meetings. As such, it agreed with the proposition that a credentials committee is entitled to the PRPA’s protections to the extent it performs a peer-review function—in this case, privileging. In short, because of Leadbitter, the PRPA’s evidentiary privilege extends to those who engage in “peer review activities” as the actual function of the committee—not the title—determines whether the privilege applies. Narrowing: Private Physician Practice Groups Cannot Assert the Privilege In 2021, the Eastern District considered whether a report authored by a radiologist who reviewed care provided at a hospital was protected under PRPA. In Lasheena Sipp Lipscob v. Einstein Physicians Pennypack Pediatrics, the plaintiff sued both a hospital and a private radiology practice that provided radiology services to the hospital, arguing the defendants failed to diagnose testicular torsion resulting in the loss of a testicle. A report generated by a radiologist employed by the practice was identified in discovery which reviewed the quality of care rendered to the plaintiff’s minor-patient. The defendants argued this report was protected under the PRPA because it was created for a “peer review purpose.” The court disagreed, reasoning first that the radiology group (i.e., a private medical practice) was not a “professional healthcare provider” within the meaning of the PRPA and therefore not eligible for the evidentiary privilege. The Pennsylvania Superior Court ruled consistent with this conclusion in 2021 in the non-precedential decision of Bousamra v. Excela Health. Second, while the hospital defendant was clearly a “professional health care provider” under the PRPA, it too could not assert the evidentiary privilege over this report because the authoring radiologist did not generate the report as part of any hospital “committee” as contemplated under the Act. In other words, because the report was not generated for or provided to any hospital “committee” performing a “peer review function,” the PRPA privilege was not extended. Key Takeaways In enacting the Peer Review Protection Act, the Pennsylvania legislature recognized that candid and rigorous clinical peer review is essential to upholding the quality of patient care. Accordingly, the evolving body of case law interpreting the PRPA’s evidentiary privilege carries substantial implications for health care providers and institutions, particularly in the context of medical malpractice litigation. To preserve the confidentiality afforded by the PRPA, documents assessing the quality of care should be created by or for a hospital committee engaged in peer review functions, such as privileging. As with any legal privilege, the integrity of protection depends on strict adherence to confidentiality—such materials must not be disclosed to unauthorized parties, whether internal or external to the institution.  The Quarterly Dose – November 2025, has been prepared for our readers by Marshall Dennehey. It is solely intended to provide information on recent legal developments and is not intended to provide legal advice for a specific situation or to create an attorney-client relationship. We welcome the opportunity to provide such legal assistance as you require on this and other subjects. If you receive the alerts in error, please send a note to tamontemuro@mdwcg.com. ATTORNEY ADVERTISING pursuant to New York RPC 7.1. © 2025 Marshall Dennehey. All Rights Reserved.

Firm Highlights

News

Marshall Dennehey’s John J. Hare Brings Home Attorney of the Year Honors; Firm Named Litigation Department of the Year in Two Categories

Marshall Dennehey took home top honors in three categories at the The Legal Intelligencer’s 2026 Pennsylvania Legal Awards, held June 11 in Philadelphia. The first place awards include: Attorney of the Year: John J. Hare, Chair of the firm’s Appellate Advocacy & Post-Trial Practice Group and Executive Committee member, together with Charles “Chip” Becker of Kline & Specter Litigation Department of the Year, Appellate – Third Win in a Row! Litigation Department of the Year, Product Liability/Mass Torts “There is no one more deserving of Attorney of the Year honors than John. This award is a testament to his exceptional skill, dedication, and leadership—qualities that truly exemplify the very best of our firm,” said G. Mark Thompson, Marshall Dennehey’s President & CEO. “These honors also reflect the strength and depth of our product liability, mass torts, and appellate practices across Pennsylvania and beyond, underscoring our ongoing commitment to delivering outstanding results for our clients.” Attorney of the Year – John J. Hare, Marshall Dennehey, together with Charles “Chip” Becker, Kline & Specter Over the past year, John and Charles were opposing counsel in many of the highest-profile civil appeals in Pennsylvania. John is renowned as a preeminent appellate lawyer on the defense side, and Chip on the plaintiff's side. They have opposed each other repeatedly, exhibiting peerless professionalism and exceptional civility, while zealously litigating under the unremitting pressure of high-profile litigation and record-setting verdicts totaling more than $3.5 billion. They have also collaborated, outside of litigation, on many commissions, committees, and projects of importance to the Pennsylvania judiciary and legal community. Litigation Department of the Year – Appellate Law, Winner (previous winner, 2025 and 2024) 2025 was another standout year for the firm’s Appellate Advocacy & Post‑Trial Practice Group, led by John J. Hare, which was retained to challenge many of Pennsylvania’s “nuclear” verdicts—awards exceeding $10 million. Notably, the department persuaded the Pennsylvania Superior Court to reverse a Philadelphia judgment of $1.09 billion, the largest judgment ever overturned by a Pennsylvania appellate court. The group’s 11 full‑time Pennsylvania‑based appellate lawyers are at the center of Pennsylvania’s most high-profile matters, bringing more than 150 years of combined appellate experience. They routinely handle post‑trial and appellate matters and are frequently engaged to participate in and monitor trials in high‑exposure cases to ensure that critical legal issues are properly raised and preserved for appeal. Litigation Department of the Year – Product Liability/Mass Torts, Winner This marks the first win for the firm’s Pennsylvania Product Liability and Mass Torts practices, which operate within our Casualty Department, managed by Matthew Schorr and Jeff Rapattoni. For almost five decades, Fortune 500 product manufacturers/distributors and their insurers have turned to these groups to defend their litigation. Led by Bradley D. Remick and Vlada Tasich, our Product Liability group’s success can be attributed to its commitment to keeping abreast of ever-changing legal theories, judicial viewpoints, and evolving technology impacting the product liability landscape. Our attorneys have successfully handled thousands of product liability matters in all jurisdictions across the state. Likewise, our mass tort litigation practice – divided into Asbestos & Mass Tort, and Environmental & Toxic Tort Litigation –  has defended manufacturers, distributors, contractors, and premises owners in thousands of personal injury and other claims. Led by Kevin E. Hexstall and Patrick T. Reilly, most attorneys in these groups have more than 20 years of experience, and our seasoned trial team has tried hundreds of cases to verdict, consistently achieving strong results through both trials and settlements. In addition to these awards, Marshall Dennehey was a Litigation Department of the Year finalist for Professional Liability.

Result

No-Cause Jury Verdict Secured in Wrongful Death Trial

We successfully obtained a no-cause jury verdict in a 13-day wrongful death trial. The decedent, a 59-year-old man, was admitted to the emergency room on February 15, 2019, with complaints of abdominal pain, decreased appetite, and constipation, despite the use of laxatives. The patient did not complain of any nausea, vomiting, or diarrhea. He had a significant medical history including diabetes, hypertension, prior coronary artery stenting, morbid obesity (with past gastric bypass surgery), longstanding ventral hernia, and back pain. A CT scan revealed multiple hernias and a potential closed-loop bowel obstruction, leading to a surgery consultation. Our client, an emergency general surgeon, interpreted that the patient did not have a closed loop or any significant obstruction and recommended non-surgical management. The patient was approved to have clear liquids, and had a vomiting incident shortly after, but our client was not notified. The patient was returned to NPO status, and after improving overnight, he was returned to “clears” and additional medical and renal consults were ordered. Our client did not receive any communications from the residents/nurses of any changes in the patient’s condition. On February 18, 2019, two rapid responses were called due to increased heart rate and vomiting. It is believed that the vomiting resulted in aspiration, causing sepsis, ultimately leading to the patient’s death. During the trial, the plaintiff’s sole medical expert highlighted imaging on the wrong hernia, which called into question all of his opinions in the case. We made key objections related to the expert testimony, limiting what the allegations were, and preventing new allegations from being made. After approximately two and a half hours of deliberating, the jury returned a no-cause verdict. 

Thought Leadership

SIDEBAR: News and Happenings

We are pleased to share that attorneys from our health care team have been selected to the 2026  New Jersey and Pennsylvania Super Lawyers and Rising Stars lists. Their dedication to clients and commitment to high-quality work continues to strengthen our firm! Please join us in congratulating: NJ Super Lawyers: Robert T. Evers and Justin F. Johnson NJ Super Lawyer Rising Stars: Nataliana A. Guida  2026 Pennsylvania Super Lawyers: Alyson J. Kirleis and Gary M. Samms 2026 Pennsylvania Rising Stars: Holli K. Archer and Daniel Dolente Victoria Scanlon (Scranton) was a faculty presenter at the 2026 American Roentgen Ray Society (ARRS) Annual Meeting in Pittsburgh. She participated in the “Resident Symposium: Producing Quality Reports,” focusing her presentation on “How to Write a Great Report: Malpractice Lawyer’s Perspective.” Vicky, the only attorney presenter for this two-hour segment, was joined by several health care professionals including diagnostic radiologists, an interventional radiologist, an internal medicine physician, and a radiologist turned AI entrepreneur expert.  Matthew Keris (Scranton), President of the Pennsylvania Association for Health Care Risk Management (PAHCRM) and shareholder in our Scranton Health Care Department, presented an important and timely session titled “Keynote Address: A Conversation with RaDonda Vaught on Criminalizing Errors” at PAHCRM’s Annual Meeting in April. RaDonda is a former Tennessee nurse widely known for being criminally convicted in 2022 of negligent homicide and gross neglect after a 2017 fatal medication error at Vanderbilt University Medical Center. Her case gained national attention because she was criminally prosecuted rather than just facing licensing board action, sparking debate over blaming individual nurses for systemic healthcare failures. Matt and RaDonda’s conversation explored one of the most consequential issues in health care risk management today—how systems respond to human error, and what it means for patient safety, accountability, and the professionals who serve on the front lines. Gary Samms was a panelist for a podcast hosted by the Medical Liability Monitor, “From Outliers to Pattern: The Increasing Predictability of Megaverdicts in the Med-Mal Industry – and How to Reduce the Likelihood of Getting Hit with One.” Gary discussed the changing megaverdict landscape and why “outlier” verdicts are becoming structural, in addition to how plaintiffs turn weaknesses into megaverdicts (including building emotional narrative and jury psychology). Thank you to our clients who joined us for our Trends in Health Care & Health Law seminar on May 14. Led by our Health Care Department Director and Assistant Director, Robin Snyder and Donna Modestine, the session explored key issues that are currently shaping outcomes in health care litigation. We owe a debt of gratitude to our esteemed guest speaker, Mary Ellen Nepps, Esq., Senior Counsel, University of Pennsylvania, who presented “Medical Malpractice Litigation: Driving Another Health Care Crisis in Pennsylvania.” And special thanks to our attorneys who presented and shared their insights, including John J. Hare and Holli Archer who discussed “Highlights in PA Medical Malpractice Law;” David Drake for his presentation, “From Claims to Courtroom: Key Trends in NJ Medical Malpractice Litigation;” and Matthew Keris with an “Update on Health Care Tech Discovery.” Thank you to all of our clients for entrusting us with your health care litigation. We are proud to partner with you as we defend your interests and navigate legal landscapes together.

Thought Leadership

Casual Care, Serious Consequences: How Informal Prescribing Can Trigger Medical Board Scrutiny

The lesson for health care practitioners is that regular review of the regulatory requirements can ensure compliance and that casual prescribing may be in violation of state regulations if the necessary components are not met. Consider the following scenario: in December 2025, a medical provider renewed a prescription for a long-standing telemedicine patient receiving a Schedule II controlled dangerous substance. This was not a violation of the New Jersey Administrative Code. Another provider doing the same action for an equally situated patient in March 2026 would be in violation. The casual prescriber who is not aware of newer regulatory requirements may have a more difficult time responding to a medical board complaint. Medicine is a highly-regulated helping profession. Without addressing the merits of this regulatory burden, the practice of medicine continues to see drastic changes impacting the everyday life of patient and provider. Telemedicine, COVID-19, and other advances and roadblocks, present a challenge to those saving lives while attempting to comply with the rules of practice. Physicians often discover—through real cases and the lens of regulatory expectations—that even well-intentioned informal help can be reinterpreted as stepping outside mandated professional boundaries, and seemingly harmless actions can be construed as deviations from required practice standards specifically outlined in Title 13, Chapter 35, Subchapters 7.1A of the New Jersey Administrative Code. Title 45, "Professions and Occupations," of the New Jersey code governs the practice of medicine, nursing, optometry, pharmacy, and many other professional occupations. Section 9 specifically addresses the state board of medical examiners and allows for the creation of rules and regulations in Section 45:9-5.3. These regulations can be found in the New Jersey Administrative Code Title 13, Chapter 35. While broad in scope, Chapter 35 contains a subchapter dedicated to the administration and dispensing of prescription drugs. Such knowledge will arm physicians with the tools they need to prevent a negative outcome if a medical board complaint is filed. Likewise, attorneys must be familiar with these regulatory requirements when advising and defending providers. In New Jersey, N.J.A.C. Section 13:35-7.1A(a) requires that a practitioner conduct an examination and appropriately document the same within the medical record before dispensing drugs or issuing prescriptions. The examination must include an "appropriate history and physical examination," a diagnosis based upon the examination and any testing consistent with good medical care, the formulation of a therapeutic plan discussed with the patient, and the availability of appropriate follow-up care. There are only six exceptions to this requirement: In admission orders for a newly hospitalized patient For a patient of another physician for whom the practitioner is taking calls For continuation medications on a short-term basis for a new patient prior to the patient's first appointment For an established patient who, based on sound medical practice, the physician believes does not require a new examination before issuing a new prescription For a patient examined by a healthcare professional who is in collaborative practice with the practitioner When treatment is provided by a practitioner for an emergency medical condition Emergencies are also limited to situations where someone's health is in serious jeopardy, there is serious impairment to bodily functions, or serious dysfunction of any bodily organ or part. During the COVID-19 pandemic, then New Jersey Governor Phil Murphy issued an executive order declaring a public health emergency and a state of emergency that allowed authorized prescribers to prescribe Schedule II controlled dangerous substances via telemedicine. The order was terminated when he left office earlier this year and the state reverted to the requirement of an initial in-person examination and quarterly in-person visits. With this return to prior regulatory requirements, practitioners subject to the jurisdiction of the board of medical examiners may benefit from a refresher on the regulatory limitations on their practice now that the pandemic-era flexibilities have ended. This new requirement may create confusion for prescribers and lead to casual prescribing of medication in violation of the regulations, even in the setting of recurrent telemedicine appointments as noted in the example above. Casual prescribing can take many forms: filling a prescription request from a friend or family member without an examination or contemporary medical record; using telemedicine to expand your practice without proper in-person appointments or documentation in the medical record; failing to ensure appropriate follow-up care for a "one time" prescription; etc. Although not all board complaints end in a publicly available opinion, serious deviations from regulatory requirements can shine a light on practices that will require action by the board if a complaint is received. Consider the following cases: In October 2025, the board issued a final consent order in an administrative action where a doctor provided opioids without examination and his license was permanently revoked. In re Robert Dela Gente, D.O., N.J. State Bd. of Med. Exam'rs Oct. 21, 2025. Criminal charges were filed (though that is not always the case). In a September 2025 consent order, a physician was reprimanded for "prescribing opioids several months in advance without the proper patient follow-up..." and explained that they did so for "patients who can not pay for multiple visits to refill medications." In re A/an E. Schultz, M.D., N.J. State Bd. of Med. Exam'rs Sept. 25, 2025. Another physician was suspended and placed on probation in a consent order for prescribing three patients the weight-loss medication "Ozempic" via text messages through a website called "Push Health" and without any further communication with the patients or taking a medical history. In re Laura E. Purdy, M.D., N.J. State Bd. of Med. Exam'rs Aug. 29, 2025. A June 2025 interim consent order required a "full evaluation and assessment of [a physician's] general knowledge and skill, with specific emphasis on his knowledge of and ability to safely prescribe [controlled dangerous substances]" due to his failure to review a patient's prior medical history and medical record, assess and review the prescription monitoring program before prescribing CDS, and conduct random urine screens on a patient that tested positive for CDS upon admission to his practice because "he trusted the patient." In re Donald Oh, M.D., N.J. State Bd. of Med. Exam'rs June 2, 2025. Each of these examples demonstrate a failure to follow strict procedure regardless of the intention. Failing to follow procedure secondary to good intentions, such as considering a patient's financial constraints, trust in the patient, or utilizing a new telemedicine service platform, will not be a defense to a board complaint. Especially when practicing via telemedicine, practitioners must ensure they are adhering to the appropriate regulatory standard. A provider who calls in a prescription for a traveling friend or family member or agrees to prescribe medication for individuals using the newest phone app will have a hard time meeting the requirements of N.J.A.C. Section 13:35-7.1A. Even if a history was taken, a "therapeutic plan" was created, and "follow up care" was provided, the prescriber would still not be in compliance with the regulation without an in-person examination. In our opening hypothetical, the prescriber's behavior did not change between December and March; however, the legal shift in the regulatory landscape made once acceptable behavior a violation as a required examination did not occur. When complaints are made with regard to informal prescribing, the board has discretion to employ measures to encourage compliance in lieu of formal proceedings such as a private, written warning; suspending fines subject to continuing compliance; medical or professional treatment as may be necessary; medical or diagnostic testing and monitoring; skills assessment; corrective training; participation in outreach programming; or contribution to the consumer fraud protection fund. The lesson for health care practitioners is that regular review of the regulatory requirements can ensure compliance and that casual prescribing may be in violation of state regulations if the necessary components are not met. Even compliant providers who had not conducted an in-person examination for telemedicine patients during the COVID-19 emergency would be in violation of the regulations as of January 2026 for the same practice. Practitioners should be diligent in adhering to the prescribing rules to avoid sanctions related to casual care. Likewise, attorneys advising or defending practitioners before the board must be aware of the in-person examination requirements for prescribing in New Jersey whether the care in question took place in-person or in a telemedicine setting. Reprinted with permission from the April 22, 2026 issue of the New Jersey Law Journal. ©2026 ALM Media Properties, LLC. Further duplication without permission is prohibited. All rights reserved.